234 related articles for article (PubMed ID: 12891224)
21. Effect of antiepileptic drug comedication on lamotrigine clearance.
Weintraub D; Buchsbaum R; Resor SR; Hirsch LJ
Arch Neurol; 2005 Sep; 62(9):1432-6. PubMed ID: 16157751
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy.
Wang Y; Zhang HN; Niu CH; Gao P; Chen YJ; Peng J; Liu MC; Xu H
Acta Pharmacol Sin; 2014 Oct; 35(10):1342-50. PubMed ID: 25220641
[TBL] [Abstract][Full Text] [Related]
23. Dose adjustment of phenytoin for comedication in Japanese patients with epilepsy.
Fukuoka N; Uno J; Tsukamoto T; Houchi H; Kimura M; Morita S
Ther Drug Monit; 2009 Feb; 31(1):57-62. PubMed ID: 19077928
[TBL] [Abstract][Full Text] [Related]
24. Amelioration of erectile dysfunction following a switch from carbamazepine to oxcarbazepine: recent clinical experience.
Sachdeo R; Sathyan RR
Curr Med Res Opin; 2005 Jul; 21(7):1065-8. PubMed ID: 16004674
[TBL] [Abstract][Full Text] [Related]
25. Pregabalin effect on steady-state pharmacokinetics of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate, and tiagabine.
Bockbrader HN; Burger P; Knapp L
Epilepsia; 2011 Feb; 52(2):405-9. PubMed ID: 21314678
[TBL] [Abstract][Full Text] [Related]
26. Effect of arachidonyl-2'-chloroethylamide, a selective cannabinoid CB1 receptor agonist, on the protective action of the various antiepileptic drugs in the mouse maximal electroshock-induced seizure model.
Luszczki JJ; Czuczwar P; Cioczek-Czuczwar A; Dudra-Jastrzebska M; Andres-Mach M; Czuczwar SJ
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):18-25. PubMed ID: 19751793
[TBL] [Abstract][Full Text] [Related]
27. Oxcarbazepine (Trileptal) in the treatment of bipolar disorders: a review of efficacy and tolerability.
Hellewell JS
J Affect Disord; 2002 Dec; 72 Suppl 1():S23-34. PubMed ID: 12589900
[TBL] [Abstract][Full Text] [Related]
28. Oxcarbazepine-induced hyponatremia and the regulation of serum sodium after replacing carbamazepine with oxcarbazepine in children.
Holtmann M; Krause M; Opp J; Tokarzewski M; Korn-Merker E; Boenigk HE
Neuropediatrics; 2002 Dec; 33(6):298-300. PubMed ID: 12571784
[TBL] [Abstract][Full Text] [Related]
29. The use of antiepileptic drugs in pediatric brain tumor patients.
Sogawa Y; Kan L; Levy AS; Maytal J; Shinnar S
Pediatr Neurol; 2009 Sep; 41(3):192-4. PubMed ID: 19664535
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
Flesch G; Czendlik C; Renard D; Lloyd P
Drug Metab Dispos; 2011 Jun; 39(6):1103-10. PubMed ID: 21389120
[TBL] [Abstract][Full Text] [Related]
31. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
32. Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders.
Grant SM; Faulds D
Drugs; 1992 Jun; 43(6):873-88. PubMed ID: 1379159
[TBL] [Abstract][Full Text] [Related]
33. Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant.
Hooper WD; Dickinson RG; Dunstan PR; Pendlebury SC; Eadie MJ
Clin Exp Neurol; 1987; 24():105-12. PubMed ID: 3268334
[TBL] [Abstract][Full Text] [Related]
34. Phenytoin and carbamazepine cross reactivity: report of a case and review of literature.
Misra UK; Kalita J; Rathore C
Postgrad Med J; 2003 Dec; 79(938):703-4. PubMed ID: 14707249
[TBL] [Abstract][Full Text] [Related]
35. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs?
Schmidt D; Elger CE
Epilepsy Behav; 2004 Oct; 5(5):627-35. PubMed ID: 15380112
[TBL] [Abstract][Full Text] [Related]
36. Oxcarbazepine and adverse events: impact of age, dosage, metabolite serum concentrations and concomitant antiepileptic therapy.
Ortenzi A; Paggi A; Foschi N; Sabbatini D; Pistoli E
Funct Neurol; 2008; 23(2):97-100. PubMed ID: 18671911
[TBL] [Abstract][Full Text] [Related]
37. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy.
Li X; Wei S; Wu H; Zhang Q; Zhao Z; Mei S; Feng W; Wu Y
Eur J Pediatr; 2023 Oct; 182(10):4509-4521. PubMed ID: 37493972
[TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy.
Peng J; Zhang HN; Liu ZS; Xu H; Wang Y
Int J Clin Pharmacol Ther; 2014 Aug; 52(8):684-92. PubMed ID: 24887335
[TBL] [Abstract][Full Text] [Related]
39. Oxcarbazepine: new preparation. An alternative to carbamazepine in partial epilepsy.
Prescrire Int; 2001 Dec; 10(56):170-4. PubMed ID: 11824439
[TBL] [Abstract][Full Text] [Related]
40. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs.
Zaccara G; Perucca E
Epileptic Disord; 2014 Dec; 16(4):409-31. PubMed ID: 25515681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
